-+ 0.00%
-+ 0.00%
-+ 0.00%

Alamar Biosciences Partners With GSK on Large-Scale Proteomics Study

PUBT·11/03/2026 21:07:26
Listen to the news
Alamar Biosciences Partners With GSK on Large-Scale Proteomics Study
  • Alamar Biosciences entered a scientific collaboration with GSK to study protein signatures linked to disease progression, biological subtypes and treatment response.
  • The study will analyze more than 60,000 serum samples using the NULISAseq Immune 340 and NULISAseq Neuro 220 panels.
  • Findings aim to support earlier disease detection, patient stratification and targeted drug development across multiple disease areas.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031603OMX_____CNEWS_EN_GNW9869318_en) on November 03, 2026, and is solely responsible for the information contained therein.